The impact of the glucagon‐like peptide‐1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The impact of the glucagon‐like peptide‐1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes

Published:2020-08-12 Issue:11 Volume:22 Page:2141-2150
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Nielsen Roni¹^ORCID,Jorsal Anders¹,Tougaard Rasmus S.¹,Rasmussen Jon J.²,Schou Morten³⁴,Videbæk Lars⁵,Gustafsson Ida⁶,Faber Jens⁴⁷,Flyvbjerg Allan⁸,Wiggers Henrik¹,Tarnow Lise⁹,Kistorp Caroline²⁴^ORCID

Affiliation:

1. Department of Cardiology Aarhus University Hospital Aarhus Denmark

2. Department of Endocrinology Rigshospitalet Copenhagen Denmark

3. Department of Cardiology Herlev‐Gentofte University Hospital Herlev Denmark

4. Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

5. Department of Cardiology Odense University Hospital Odense Denmark

6. Department of Cardiology Fredriksberg University Hospital Fredriksberg Denmark

7. Department of Endocrinology Herlev‐Gentofte University Hospital Herlev Denmark

8. Steno Diabetes Center Copenhagen Denmark

9. Steno Diabetes Center Sjaelland Holbaek Denmark

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14135

Reference38 articles.

1. Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM‐HF);Okumura N;Circulation.,2016

2. Oral glucose tolerance testing in an outpatient heart failure clinic reveals a high proportion of undiagnosed diabetic patients with an adverse prognosis;Egstrup M;Eur J Heart Fail.,2011

3. Liraglutide and cardiovascular outcomes in type 2 diabetes;Marso SP;N Engl J Med.,2016

4. The cardiovascular biology of glucagon‐like peptide‐1;Drucker DJ;Cell Metab.,2016

5. Cardiovascular, mortality, and kidney outcomes with GLP‐1 receptor agonists in patients with type 2 diabetes: a systematic review and meta‐analysis of cardiovascular outcome trials;Kristensen SL;Lancet Diabetes Endocrinol.,2019

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natriuretic peptide system in hypertension: Current understandings of its regulation, targeted therapies and future challenges;European Journal of Pharmacology;2024-08

2. Semaglutide ameliorates pressure overload-induced cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome;Scientific Reports;2024-05-23

3. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials;Medicine;2024-03-15

4. Natriuretic peptide testing strategies in heart failure: A 2023 update;Advances in Clinical Chemistry;2024

5. Evaluating the bioequivalence and safety of liraglutide injection versus Victoza® in healthy Chinese subjects: a randomized, open, two-cycle, self-crossover phase I clinical trial;Frontiers in Pharmacology;2023-12-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3